Hologic, Inc. (Nasdaq: HOLX) announced today that its Aptima ® HPV Assay received FDA approval for clinician-collected HPV primary screening. Hologic’s human papillomavirus (HPV) test is the only ...

The FDA has expanded the approval of Hologic’s Aptima human papillomavirus (HPV) assay for clinician-collected primary ...

The US Food and Drug Administration (FDA) has granted 510(k) clearance to Hologic's Aptima SARS-CoV-2 assay, marking an advancement since its initial emergency use authorisation (EUA) was granted in ...

The US Food and Drug Administration (FDA) has approved Hologic, Inc.'s Aptima HPV 16 18/45 genotype assay for use on the company's fully automated Panther system. The Aptima HPV 16 18/45 genotype ...

Hologic, Inc. announced today that Health Canada has granted medical device licenses for Hologic's APTIMA HPV and APTIMA HPV 16 18/45 genotype assays. Both assays are in vitro nucleic acid ...

MARLBOROUGH, Mass.--(BUSINESS WIRE)-- Hologic, Inc. (NASDAQ: HOLX) announces the addition of the Aptima® SARS-CoV-2 assay to its Global Access Initiative (GAI), a program designed to expand access to ...

Hologic, Inc. HOLX recently expanded its Global Access Initiative (“GAI”) with the addition of the Aptima SARS-CoV-2 assay. The GAI’s all-inclusive pricing structure is anticipated to make the Aptima ...

MARLBOROUGH, Mass.--(BUSINESS WIRE)-- Hologic, Inc. (Nasdaq: HOLX) has received CE mark for its new Aptima® CMV Quant assay in Europe, the Company announced today. This assay, which quantifies the ...

MARLBOROUGH, Mass.--(BUSINESS WIRE)-- Hologic, Inc. (HOLX) announced today that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the company’s Aptima® SARS-CoV-2 assay, ...

MARLBOROUGH, Mass.--(BUSINESS WIRE)--Hologic, Inc. (Nasdaq: HOLX) announced today that its new Genius™ Digital Diagnostics System is now CE marked in Europe. Genius Digital Diagnostics is the first ...